Typical Compounded Bi-Est Liposomal Cream Dosing
There is no standardized, evidence-based dosing for compounded Bi-Est cream, and these products lack FDA approval with significant concerns about safety, efficacy, and variable estrogen exposure compared to FDA-approved alternatives. 1, 2
Critical Context on Compounded Bioidentical Hormones
The FDA has not approved any compounded bioidentical hormone therapy, and "bioidentical hormone replacement therapy" is a marketing term rather than a formally defined drug classification. 1 No randomized trials have studied the potential benefits or harms of bioidentical hormones for either symptom management or prevention of chronic conditions in postmenopausal women. 1
Commonly Used Dosing Ranges (Despite Lack of Evidence)
Based on limited pharmacokinetic research and product labeling, compounded Bi-Est creams are typically prescribed in the following ranges:
The product labeling suggests application once or twice daily to inner arms, thighs, chest, or inner forearm. 4
Major Safety and Efficacy Concerns
Compounded estradiol creams deliver significantly lower estrogen exposure than FDA-approved patches and gels at comparable doses. 3 A 2023 study demonstrated that urinary estradiol concentrations from compounded creams were significantly lower across all dose ranges compared to FDA-approved transdermal formulations (P < 0.001 for mid-dose range). 3
A 2013 pharmacokinetic trial found that all tested doses of Bi-Est cream (2.0,2.5, and 3.0 mg) yielded consistently lower estrogen levels compared to a standard 0.05 mg estradiol patch. 5 The differences were statistically significant:
- Bi-Est 2.0 mg: AUC-estradiol 181 vs. 956 for patch (p<0.001) 5
- Bi-Est 2.5 mg: AUC-estradiol 286 vs. 917 for patch (p<0.001) 5
- Estriol levels remained low across all study arms 5
Professional Society Recommendations
The American College of Obstetricians and Gynecologists (ACOG) states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. 2 Clinicians should counsel patients that FDA-approved menopausal hormone therapies are recommended over compounded preparations. 2
If a patient insists on compounded therapy, clinicians must educate them on:
- Lack of FDA approval 2
- Absence of standardized pharmacokinetic data 5, 3
- Potential risks specific to compounding (contamination, incorrect dosing, lack of quality control) 2
- Significantly lower estrogen exposure than expected based on labeled dose 3
Clinical Pitfalls to Avoid
Do not assume dose equivalency between compounded creams and FDA-approved products. Women switching from compounded Bi-Est cream to FDA-approved transdermal estradiol may experience higher estrogen exposure than anticipated, requiring dose adjustment. 3
Estriol contributes minimally to overall estrogen exposure. Despite comprising 80% of Bi-Est formulations, estriol levels remain low and likely provide negligible therapeutic effect. 5
The 80:20 estriol:estradiol ratio lacks evidence-based justification. This formulation is based on marketing claims rather than clinical trial data demonstrating superiority or safety. 1, 2
Evidence-Based Alternative Approach
For women seeking menopausal symptom relief, FDA-approved transdermal estradiol (patches or gels) with appropriate progestin protection (if uterus intact) provides:
- Standardized dosing with predictable pharmacokinetics 3
- Extensive safety and efficacy data 1
- FDA-mandated quality control and labeling 2
- Package inserts detailing risks and benefits 6
If a patient has legitimate need for compounded therapy (true allergy to FDA-approved formulations or unavailable dosing/formulation), this should be the rare exception, not routine practice. 2, 6